Thermo Fisher Scientific and Daiichi Sankyo have agreed to co-develop a companion test for patients with non-small cell lung cancer (NSCLC).
Their collaboration will focus on identifying HER2 gene mutations using Thermo Fisher's next-generation sequencing-based Oncomine Dx Target test. The companion test will be used to identify patients eligible for treatment with trastuzumab deruxtecan (Enhertu), a HER2 directed antibody drug conjugate developed by Daiichi Sankyo and Astra Zeneca that is currently in global phase II development for HER2-mutated or HER2-overexpressing NSCLC.
Thermo Fisher will retain rights to commercialize the test globally and will seek approval from regulatory agencies. This announcement follows a 2018 agreement between the companies to expand the clinical utility of the test in support of clinical trials and drug development programs at Daiichi Sankyo.
